Literature DB >> 7747319

Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 19 May 1994. Trypanosomiasis and the nervous system. Pathology and immunology.

V W Pentreath1.   

Abstract

Damage to the nervous system occurs in both African and American trypanosomiases, but it differs considerably in form and extent in each disease, and with different strains and disease stages. With Trypanosoma brucei infections there is a progressive central nervous system (CNS) pathology which involves the meninges, choroid, blood-brain barrier, and immunopathological changes including perivascular infiltrations, astrocyte activation and alterations in the cytokine/mediator network. These changes underly the altered behaviour in the late or secondary disease stages, prevalent in the chronic gambian form, characterized by hypersomnia leading, if untreated or if treatment is followed by reactive changes, to coma and death. T. cruzi infections can be divided into 3 stages; acute, intermediate and chronic. Each stage has a different neurological involvement. In the acute stage the parasite produces direct destructive and inflammatory changes in the CNS which can be life-threatening, but which normally resolve, giving way to an intermediate period with effective parasite suppression and little or no perpetuation in the nervous system. The chronic stage is characterized by alteration to a progressive peripheral neuroimmunopathology, with autoimmune destruction of many nerve components, especially the autonomic innervation of the heart and gut.

Entities:  

Mesh:

Year:  1995        PMID: 7747319     DOI: 10.1016/0035-9203(95)90637-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  9 in total

Review 1.  Human African trypanosomiasis of the CNS: current issues and challenges.

Authors:  Peter G E Kennedy
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

2.  Cross-reactivity of anti-galactocerebroside autoantibodies with a Trypanosoma brucei proteolipidic epitope.

Authors:  M Girard; S Bisser; P Buscher; B Bouteille; J L Preud'homme; M O Jauberteau
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

3.  Late stage infection in sleeping sickness.

Authors:  Hartwig Wolburg; Stefan Mogk; Sven Acker; Claudia Frey; Monika Meinert; Caroline Schönfeld; Michael Lazarus; Yoshihiro Urade; Bruno Kilunga Kubata; Michael Duszenko
Journal:  PLoS One       Date:  2012-03-27       Impact factor: 3.240

4.  Intravital imaging of a massive lymphocyte response in the cortical dura of mice after peripheral infection by trypanosomes.

Authors:  Jonathan A Coles; Elmarie Myburgh; Ryan Ritchie; Alana Hamilton; Jean Rodgers; Jeremy C Mottram; Michael P Barrett; James M Brewer
Journal:  PLoS Negl Trop Dis       Date:  2015-04-16

5.  Cyclical appearance of African trypanosomes in the cerebrospinal fluid: new insights in how trypanosomes enter the CNS.

Authors:  Stefan Mogk; Andreas Meiwes; Swetlana Shtopel; Ulrich Schraermeyer; Michael Lazarus; Bruno Kubata; Hartwig Wolburg; Michael Duszenko
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

6.  Early invasion of brain parenchyma by African trypanosomes.

Authors:  Ute Frevert; Alexandru Movila; Olga V Nikolskaia; Jayne Raper; Zachary B Mackey; Maha Abdulla; James McKerrow; Dennis J Grab
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

7.  Chemotherapy of human african trypanosomiasis.

Authors:  Cyrus J Bacchi
Journal:  Interdiscip Perspect Infect Dis       Date:  2009-08-20

Review 8.  Gastrointestinal Parasites and the Neural Control of Gut Functions.

Authors:  Marie C M Halliez; André G Buret
Journal:  Front Cell Neurosci       Date:  2015-11-25       Impact factor: 5.505

Review 9.  The role of cytokines in the pathogenesis and staging of Trypanosoma brucei rhodesiense sleeping sickness.

Authors:  Charles D Kato; Enock Matovu; Claire M Mugasa; Ann Nanteza; Vincent P Alibu
Journal:  Allergy Asthma Clin Immunol       Date:  2016-01-22       Impact factor: 3.406

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.